Robert Davis, Merck CEO
June 22, 2022 10:27 AM EDT
Deals
Bioregnum

In lieu of hard M&A news, one group of an­a­lysts crunch­es the num­bers around a $40B Seagen buy

Some of the an­a­lysts at SVB Se­cu­ri­ties have been play­ing with the num­bers that might set the stage for Mer­ck $MRK — or some oth­er Big …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Judge halts some NIH cuts af­ter 22 states sue

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date

Decade af­ter $8B deal, Roche of­floads In­ter­Mune to mys­te­ri­ous spe­cial­ty phar­ma

Boehringer In­gel­heim touts suc­cess in sec­ond Phase 3 lung fi­bro­sis tri­al

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times